Trevena (6T4) Stock Price & Analysis
6T4 Stock Chart & Stats
- Day’s Range
- EUR 3.82 - EUR 5.20
- 52-Week Range
- EUR 3.82 - EUR 5.20
- Previous Close
- EUR 3.82
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 8,585
- Enterprise Value
- EUR 27.01M
- Total Cash (Recent Filing)
- EUR 13.46M
- Total Debt (Recent Filing)
- EUR 37.56M
- Price to Earnings (P/E)
- ―
- Beta
- N/A
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Product Portfolio
OLINVYK's FDA approval for acute pain management provides a strong foundation for Trevena's product portfolio, supporting long-term revenue potential in the pain management sector.
Strategic Partnerships
Strategic partnerships and licensing agreements enhance Trevena's ability to expand its market reach and leverage external expertise, contributing to sustainable growth.
Leadership Stability
The appointment of Katrine Sutton as CFO, with her extensive industry experience, is expected to strengthen financial management and strategic decision-making, supporting long-term stability.
Bears Say
Financial Health
Trevena's negative equity and ongoing losses highlight severe financial instability, posing significant long-term risks to its operational sustainability and ability to invest in growth.
Revenue Decline
The sharp decline in revenue growth indicates weakening market demand or competitive pressures, challenging Trevena's ability to maintain its market position and grow its business.
Cash Flow Issues
Deteriorating cash flow generation limits Trevena's financial flexibility, impacting its capacity to fund operations, invest in R&D, and manage debt, threatening long-term viability.
6T4 FAQ
What was Trevena’s price range in the past 12 months?
What is Trevena’s market cap?
When is Trevena’s upcoming earnings report date?
How were Trevena’s earnings last quarter?
Is Trevena overvalued?
Does Trevena pay dividends?
What is Trevena’s EPS estimate?
How many shares outstanding does Trevena have?
What happened to Trevena’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Trevena?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Trevena
Trevena, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing innovative pharmaceutical solutions for individuals suffering from central nervous system disorders. Its pipeline features several promising drug candidates: OLINVYK (Oliceridine) injection: A G protein-biased mu-opioid receptor (MOR) ligand engineered to manage acute pain ranging from moderate to severe. TRV027: Aimed at addressing acute lung injury, which contributes to acute respiratory distress syndrome (ARDS) and abnormal blood clotting in patients with COVID-19. TRV250: A G protein-biased delta-opioid receptor agonist under development for the treatment of acute migraine. TRV734: A small molecule G protein-biased MOR ligand designed for the management of both moderate-to-severe acute and chronic pain. TRV045: An innovative S1P modulator focused on providing relief for chronic pain. The company has also established a partnership with Imperial College London to investigate TRV027's potential in patients afflicted with COVID-19. Trevena, Inc., founded in 2007, operates from its headquarters in Chesterbrook, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Carrie L. Bourdow
- Employees
- 23
- Website
- www.trevena.com
- Address
- 955 Chesterbrook Boulevard, Chesterbrook, PA, 19087, US
Trevena (6T4) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 10 | 0 | 4 |
| Technical Analysis | 2 | 0 | 0 |
| Moving Averages | 8 | 0 | 4 |









